Day: February 12, 2021

Owning a car is a matter of pride and considering the current situation across the world, it has become essential to own a vehicle for daily commute. It is not safe to use public transport and you never know how long it will take for normalcy to return. This is the best time to invest in a car of your choice and you can easily get a loan against car from Hero FinCorp. The lender enjoys a strong reputation in the industry and is one of the most trusted. They have a presence across the length and breadth of the country. Hero FinCorp has helped several individuals turn their dreams into a reality and they strive to make the process of owning a car quick and convenient for you. Hero FinCorp does not have a long and tedious application procedure. If you want to own a car, you simply need to be above the age of 21 and have a valid driving license....

Major indices started the market with positive ticks but ended with small declines after reaching intraday record highs this Wednesday afternoon. Investors are torn and still assessing whether the latest inflation report will have a big effect for the proposed coronavirus aid bill. Both Nasdaq and S&P500 dropped a bit after it hits record highs in the start of the morning session while the Dow on the other side ended up higher. Treasuries fell while Gold and Silver ended up mixed. Below are the main movements in the Stock Market after 4:00 p.m. Wednesday; – S&P500 dropped less than 0.1% to 3,909.90.– The Dow Jones Industrial Average rose about 0.20% or is higher by 62.57 points to 31,438.90.– Nasdaq Composite declined quite a bit and is down by 0.25% or 35.16 points lower to 13,972.53.– The Stoxx Europe...

FRAMINGHAM, Mass., Feb. 12, 2021 (GLOBE NEWSWIRE) — Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), developer of novel self-assembling wound care and biosurgical devices, today announced that it has entered into securities purchase agreements with certain institutional and accredited investors to raise approximately $6.9 million through the issuance of an aggregate 43,125,002 shares of its common stock and warrants to purchase up to an aggregate of 32,343,751 shares of common stock, at a combined purchase price of $0.16 per share of common stock and associated warrant in a private placement. The closing of the private placement is expected to occur on or about February 17, 2021, subject to the satisfaction of customary closing conditions.H.C. Wainwright & Co. is acting as exclusive placement agent for the offering.The...

SASKATOON, Saskatchewan, 12 févr. 2021 (GLOBE NEWSWIRE) — Cameco (TSX: CCO; NYSE: CCJ) annonce aujourd’hui ses résultats financiers et d’exploitation consolidés pour le quatrième trimestre et l’exercice se terminant le 31 décembre 2020 conformément aux Normes internationales d’information financière (IFRS).« À l’approche du début de 2021, les paramètres fondamentaux à long terme du marché de l’uranium nous donnent des raisons de rester optimistes, déclare le président et chef de la direction de Cameco, Tim Gitzel. Partout dans le monde, on assiste à un intérêt croissant pour l’électrification, et ce, pour diverses raisons. Il y a les endroits qui mettent en place leur approvisionnement énergétique de base, ceux qui cherchent une solution de remplacement aux sources de combustibles fossiles,...

MENLO PARK, Calif., Feb. 11, 2021 (GLOBE NEWSWIRE) — Talis Biomedical Corporation (Nasdaq: TLIS), a company dedicated to developing innovative molecular diagnostic tests for infectious diseases at the point-of-care, today announced the pricing of its initial public offering of 13,800,000 shares of its common stock at a public offering price of $16.00 per share. The gross proceeds to Talis from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Talis, are expected to be approximately $220.8 million. In addition, Talis has granted the underwriters a 30-day option to purchase up to 2,070,000 additional shares of its common stock at the initial public offering price, less the underwriting discounts and commissions. All of the shares are being offered by Talis.Talis has been approved...

REHOVOT, Israel, Feb. 11, 2021 (GLOBE NEWSWIRE) — CollPlant Biotechnologies (NASDAQ:CLGN), today announced that it has entered into definitive agreements with several healthcare-focused and other institutional investors for the purchase and sale of 2,000,000 of the Company’s American Depositary Shares (ADSs), at a purchase price of $17.50 per ADS, in a registered direct offering. Each ADS represents one (1) ordinary share, par value NIS 1.50 per share, of CollPlant. The offering is expected to close on or about February 17, 2021, subject to satisfaction of customary closing conditions.H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.The gross proceeds from the offering, before deducting the placement agent’s fees and other offering expenses payable by the Company, are expected to be ...

MIAMI, Feb. 11, 2021 (GLOBE NEWSWIRE) — Longeveron Inc. (NASDAQ:LGVN) (“Longeveron” or “Company”), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today announced the pricing of an underwritten initial public offering of 2,660,000 shares of common stock at a public offering price of $10.00 per share for aggregate gross proceeds of $26,600,000 prior to deducting underwriting discounts, commissions, and other offering expenses. In addition, the Company has granted the underwriters a 30-day option to purchase up to an additional 399,000 shares at the public offering price less the underwriting discounts and commissions. The offering is expected to close on February 17, 2021, subject to satisfaction of customary closing conditions.The...